EP. 1: Defining Suboptimal Response to BCR-ABL TKI Therapy in CML
EP. 2: Alternative Mechanism for Treatment of Resistant CML
EP. 3: Experience with Omacetaxine for TKI-Resistant TKI CML
EP. 4: Toxicity for Omacetaxine in CML
EP. 5: Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma